Your browser version may not work well with NCBI's Web applications. More information here...
1: Br J Haematol. 2006 Apr;133(1):78-82.Click here to read Links
Erratum in:
Br J Haematol. 2006 May;133(4):452.

Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia.

Leytin V, Mykhaylov S, Starkey AF, Allen DJ, Lau H, Ni H, Semple JW, Lazarus AH, Freedman J.

Division of Transfusion Medicine, Department of Laboratory Medicine, St Michael's Hospital, Toronto, ON, Canada. leytinv@smh.toronto.on.ca

We have previously shown that injection of anti-glycoprotein (GP) IIb induces murine immune thrombocytopenia (ITP) and that intravenous immunoglobulin (IVIg) ameliorates ITP. We hypothesise that murine ITP may be associated with platelet apoptosis, which is upregulated by anti-GPIIb and downregulated by IVIg. The current study demonstrated that anti-GPIIb injection induced three critical apoptosis manifestations in platelets: (i) mitochondrial inner transmembrane potential (delta psi m) depolarisation; (ii) caspase-3 activation; and (iii) phosphatidylserine (PS) exposure. IVIg administration inhibited caspase-3 activation and PS exposure, but not delta psi m-depolarisation, in anti-GPIIb-treated platelets, demonstrating that IVIg ameliorates thrombocytopenia concomitantly with inhibiting late, but not early mechanisms of platelet apoptosis.

PMID: 16512832 [PubMed - indexed for MEDLINE]

Patient Drug Information